Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.

Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020 Jan; 34(1):112-118.

View in: PubMed

subject areas

Adult
Antibodies, Monoclonal, Humanized
Cohort Studies
Dermatologic Agents
Europe
Female
Genetic Variation
Humans
Interleukin-17
Male
Middle Aged
Open Reading Frames
Pharmacogenomic Testing
Psoriasis
Treatment Outcome
Untranslated Regions

authors with profiles

Mark Talamonti